Secondary Logo

Journal Logo

Errata

International Clinical Psychopharmacology: November 2004 - Volume 19 - Issue 6 - p 363
ERRATA
Free

Erratum

In Table 4 of the article “Evidence based review of escitalopram in treating major depressive disorder in primary care” (Einarson, 2004), some of the values for escitalopram and citalopram were transposed. The escitalopram nausea rate should be 14.7% overall (not 17.6%). The escitalopram headache rate overall should be 10.2% (not 12.9%). The numbers for escitalopram and citalopram are reversed. Escitalopram should be 3.8% overall (not 7.0%) and citalopram should be 7.0%, not 3.8%. The corrected table follows:

Table 4

Table 4

Erratum

In the legend to Figure 5 of the article “Maintenance of long-term efficacy and safety of quetiapine in the open-label treatment of schizophrenia”, the treatment time should read 208 and not 280 weeks. The correct legend follows:

Fig. 5. Mean±SD change in weight (kg) from baseline over 208 weeks of open-label treatment.

Back to Top | Article Outline

Reference

Einarson TR. Evidence based review of escitalopram in treating major depressive disorder in primary care. Int Clin Psychopharmacology 19:305–310.
    Kasper S, Brecher M, Fitton L, Jones AM. Maintenance of long-term efficacy and safety of quetiapine in the open-label treatment of schizophrenia. Int Clin Psychopharmacology 19:281–289.
      © 2004 Lippincott Williams & Wilkins, Inc.